NAFLD (Non-alcoholic Fatty Liver Disease)Phase 1NCT07128797
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
A Phase 1 study testing B1344 in people with NAFLD (Non-alcoholic Fatty Liver Disease) and NASH (Nonalcoholic Steatohepatitis), run by Tasly Biopharmaceuticals Co., Ltd. at 5 sites in China.
Trial summary
This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with NAFLD. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)
- What is being tested?
- B1344
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 5 sitesChina
- Study dates
- 24 Jul 2025to Jul 2026
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chinese patients aged between 18 and 75 years;
- Patients diagnosed with NAFLD and with a magnetic resonance proton density fat fraction (MRI-PDFF) ≥10% in the screening/baseline period or within one month prior;
- Presence of any one of the following metabolic risk factors:
- Body Mass Index (BMI) ≥24.0 kg/m² or abdominal obesity (male waist circumference ≥90 cm, female waist circumference ≥85 cm);
- Fasting blood glucose ≥6.1 mmol/L, or 2-h blood glucose after glucose load ≥7.8 mmol/L, or glycated hemoglobin (HbA1c) ≥5.7%, or history of type 2 diabetes, or Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR) ≥2.5;
- Resting blood pressure ≥130/85 mmHg, or currently receiving antihypertensive medication;
Show all 10Show fewer
- Fasting serum triglycerides (TG) ≥1.70 mmol/L, high-density lipoprotein cholesterol (HDL-c) ≤1.0 mmol/L (male) and 1.3 mmol/L (female), or currently receiving lipid-lowering medication.
- Weight stability reported by participants within 6 weeks before enrollment (absolute weight change ≤5%).
- Participants have no fertility plans within 3 months after signing the informed consent and voluntarily take effective contraceptive measures.
- Voluntary participation in the clinical trial, able to sign the informed consent, and capable of understanding and complying with the trial procedures.
Who cannot join
- Liver biopsy, or clinical diagnosis of cirrhosis based on clinical presentation, biochemical and imaging results, or any of the following criteria: ① FIB-4 score ≥3.48 in the screening/baseline period or within 1 month prior, or liver stiffness value (LSM) ≥15 kPa based on FibroScan; ② liver biopsy results indicating NASH-F4 stage within the previous 24 months; ③ clinical examination signs of liver cirrhosis or splenomegaly during the screening/baseline period; ④ abdominal imaging results showing liver nodules or splenomegaly during the screening/baseline period or within 1 month prior.
- History of tumors or liver transplantation, or patients planning to undergo liver transplantation.
- History of liver diseases other than NAFLD or clinical suspicion of liver diseases other than NAFLD, including but not limited to secondary NAFLD, hepatitis B, hepatitis C, autoimmune hepatitis, hemochromatosis, alcoholic liver disease, primary sclerosing cholangitis, primary biliary cholangitis, or Wilson's disease.
- History of other diabetes besides T2DM (such as type 1 diabetes, secondary diabetes, etc.), or currently using or planning to use insulin, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) analog drugs for treatment.
- Presence of other severe, progressive, or uncontrolled diseases besides T2DM, hypertension, and dyslipidemia, including but not limited to immune system, endocrine system, hematologic system, urinary system, hepatobiliary system, respiratory system, nervous system, psychiatric system, cardiovascular system, digestive system, where participation in this trial would increase participant risk as determined by the investigator.
- Previous history of weight-loss surgery or plans for weight-loss during the trial, or significant changes in exercise or dietary habits.
Show all 35Show fewer
- History of extra-bone injury, fracture, or bone-related surgery within 2 months before screening.
- Participants with a history of long QT syndrome or family history of sudden death, or males with QTcF > 450 ms, females with QTcF > 470 ms.
- Allergic to B1344 or its excipients, or history of allergy to other biological products or severe allergic reactions.
- History of drug use related to secondary NAFLD lasting more than 2 weeks within 12 months before screening, including amiodarone, methotrexate, systemic corticosteroids, 5-fluorouracil, irinotecan, tetracycline, tamoxifen, doses exceeding hormone replacement estrogen, anabolic steroids, valproic acid, and other known hepatotoxic drugs.
- History of concomitant treatment that does not meet protocol requirements before enrollment, or concomitant treatment that meets protocol requirements but cannot maintain a stable dose until the end of the trial, or plans to initiate new concomitant treatments after the first dose until the end of the trial.
- Previous use of FGF-21 analogs or FGFR1 agonists.
- Screening/baseline examination results meeting the following criteria:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 times the upper limit of normal (ULN), total bilirubin >ULN;
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m²;
- Hemoglobin <120 g/L (male) or <110 g/L (female);
- HbA1c ≥9%; fasting blood glucose ≥13.9 mmol/L;
- International normalized ratio (INR) >1.3;
- Platelet count <110×10⁹/L;
- Dual-energy X-ray absorptiometry (DXA) T-score ≤-2.5;
- Resting systolic blood pressure <90 or ≥160 mmHg, resting diastolic blood pressure <50 or ≥100 mmHg;
- Resting heart rate <60 or >100 beats/minute;
- TG ≥5.65 mmol/L;
- Hepatitis B surface antigen (HBsAg) positive, hepatitis C antibody (HCVAb) positive, human immunodeficiency virus (HIV) antibody positive, or positive for serum Treponema pallidum specific antibody (TP-Ab).
- History of long-term excessive alcohol consumption, or alcohol consumption ≥14 World Health Organization (WHO) alcohol units per week (1 WHO alcohol unit = 10 g pure alcohol) within 3 months before screening, or positive alcohol screening, or unable to refrain from alcohol 48 hours before the first dose until the end of the trial.
- Excessive consumption of tea, coffee, or caffeinated beverages (daily consumption of more than 8 cups of respective drinks, with 1 cup being 250 mL) within 3 months before screening, or consumption of any caffeinated food or drink (such as coffee, strong tea, chocolate, cola, etc.) within 48 hours before the first dose.
- History of blood donation, loss of blood ≥200 mL, blood transfusion, or use of blood products within 3 months before screening, or plans to donate blood during the trial.
- History of needle phobia, blood phobia, or frequent episodes of orthostatic hypotension, or inability to tolerate venipuncture.
- History of drug abuse, or positive urine drug abuse screening.
- Smoking more than 5 cigarettes daily within the last 3 months or cannot completely quit smoking during the trial.
- Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during the trial.
- Any skin or abdominal wall anomalies that would affect subcutaneous injection, or tattoos or scars covering more than 50% of the abdominal wall surface area.
- Participation in other clinical trials and receiving trial interventions within the last 3 months.
- Existing MRI examination contraindications or inability to cooperate with MRI examinations before screening.
- Other circumstances deemed unsuitable for participation in this trial by the investigator.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
China5 sites, 5 recruiting
- Recruiting
Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University
Beijing, Beijing Municipality
Lai Wei
- Not yet recruiting
Sinopharm Tongmei General Hospital
Datong, Shanxi
Xiujun Li
- Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong
Jinjun Chen
Chongyuan Xu
- Not yet recruiting
The First Affiliated Hospital to Nankai University
Tianjin, Tianjin Municipality
Tao Han
- Not yet recruiting
The First Affiliated Hospital to Wenzhou Medical University
Wenzhou, Zhejiang
Minghua Zheng
About this study
Official title: A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Subcutaneous Injections of B1344 Injection in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with NAFLD. Additionally, the trial will conduct preliminary observations on the efficacy of B1344, aiming to provide early proof of concept for B1344 as a therapeutic agent for NASH.
- Being tested
- B1344, Placebo
- Medical subject headings
- Non-alcoholic Fatty Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
B1344Drug
Subcutaneous injection
PlaceboOther
Subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| B1344 30mg weekly (QW) | Experimental | Not described Receives: Drug: B1344 |
| B1344 45mg weekly (QW) | Experimental | Not described Receives: Drug: B1344 |
| B1344 60mg Every 2 Weeks (Q2W) | Experimental | Not described Receives: Drug: B1344 |
| B1344 90mg Every 2 Weeks (Q2W) | Experimental | Not described Receives: Drug: B1344 |
| Placebo QW or Q2W | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency and severity of Adverse Events (AEs) and Serious Adverse Events
Measured: 113 days
Secondary outcomes (13)
The maximum observed serum concentration (Cmax) of B1344.
Measured: 113 days
Time to peak serum concentration (Tmax) of B1344
Measured: 113
Area under the serum concentration versus time curve from time zero to the last measurable concentration (AUClast) of B1344
Measured: 113
Terminal elimination half-life (t1/2) of B1344
Measured: 113
Compare the changes in triglycerides (TG) after administration compared to the baseline, as well as the percentage changes.
Measured: 90 days
Absolute Change From Baseline in Hepatic Fat Fraction Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at day 90.
Measured: 90 days
Percent Change From Baseline in Hepatic Fat Fraction Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at day 90.
Measured: 90 days
The proportion of participants with ≥30% relative fat reduction on MRI-PDFF compared to the baseline at day 90
Measured: 90 days
Absolute Change and Percent Change From Baseline in HbA1c at day 90.
Measured: 90 days
The proportion of participants with ≥17U/L reduction on ALT compared to the baseline at day 90.
Measured: 90 days
Absolute Change and Percent Change From Baseline in ALT and AST at day 90.
Measured: 90 days
Absolute change and percent change from baseline in pro-C3 based on Fibroscan liver stiffness measurement (LSM) at day 90.
Measured: 90 days
Absolute Change and Percent Change From Baseline in Body Weight at Day 90.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2025
- Study start24 Jul 2025
- Primary completionJun 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NAFLD (Non-alcoholic Fatty Liver Disease)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07128797
- Sponsor's protocol ID
- TASLY-BM-B1344-NASH-Ib
- Status last verified
- Jul 2025
- First submitted
- 9 Jul 2025
- Last updated
- 19 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided